Likewise, a significantly higher frequency of TERT promoter mutations (72.7% vs. 25.6%; p = 0.0005, Fisher’s Exact Test) and HRAS mutations (0% vs. 18.2%; p = 0.014, Fisher’s Exact Test) was evident in non-muscle-invasive versus muscle-invasive samples for the first time in UTUC cohort (Figure 4B). Here, TERT is linked to renal pelvis/ureter urothelial carcinoma.